• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Invuity prez & CEO Sawyer steps down, Flora in as interim | Personnel Moves – March 13, 2018

Invuity prez & CEO Sawyer steps down, Flora in as interim | Personnel Moves – March 13, 2018

March 13, 2018 By Fink Densford

Invuity

Invuity (NSDQ:IVTY) said late last week that its president and chief executive officer Philip Sawyer has resigned and will be replaced by board member Scott Flora on an interim basis.

Flora has served as a member of the board since last November, and has held positions as prez, CEO and director of Omniguide. He has also held executive positions at Smith & Nephew (NYSE:SNN), including prez and GM of the orthopedics reconstruction division, GM of the trauma and clinical therapies division and senior VP of US & Europe.

“Phil is a truly visionary leader who over his eight years as president and CEO launched the company, led the initial public offering, introduced incredibly innovative new products and hired great talent. As the company has moved to its next phase, now is the perfect time to bring in a CEO who will execute on the company’s vision and move forward towards profitability while scaling the organization. On behalf of the board we appreciate the contributions that Phil has made to the company and wish him well in his future endeavors. Scott is uniquely qualified to lead Invuity in an interim capacity.  He brings executive leadership experience and domain expertise from his deep experience in the medical device industry.  Additionally, Scott has a familiarity with Invuity from his prior consulting role with the Company, and his recent appointment to the Board, that will enable him to seamlessly step into the interim President and CEO role,” board chair Gregory Lucier said in a prepared statement.

Board chair Lucier said that the company is currently searching for a permanent CEO.

“I am enthusiastic about deepening my relationship with Invuity. I look forward to building on Phil’s work and leading the organization during this interim period. We have terrific employees and customers that are excited about our technology,” Flora said in a press release.

 Endospan taps ex-Endologix exec Mayberry as CEO

Endovascular device developer Endospan said yesterday it tapped former Endologix exec Kevin Mayberry as its new chief executive officer, replacing Alon Shalev, who will stay on as a director.

Prior to his time with Endospan, Mayberry operated in various R&D and executive positions at Endologix after joining the company in 2004. Most recently, Mayberry acted as Asia-Pacific operations regional sales director, based in Singapore.

“This is a very exciting time to be joining Endospan. We have submitted for European approval of our Nexus Stent Graft System, the first off-the-shelf endovascular approach to treating aortic arch disease including aneurysms and dissections. While minimally invasive techniques are standard of care for treating descending aortic disease and heart disease, unfortunately the bridge between the two in the difficult-to-treat aortic arch anatomy is vastly underserved and remains a very invasive, high-mortality open surgery. More than 120,000 patients suffer thoracic aortic arch disease every year in the US and Europe, but only about 25% are diagnosed or treated. This global market opportunity already is greater than $1.3 billion in a segment with no off-the-shelf endovascular options. Consequently, we fully expect NEXUS will be embraced by cardiologists as well as cardiac and vascular surgeons,” Mayberry said in a press release.

Read more

 Physeon names Kullmann as CEO

Vascular medical device developer Physeon said last week it named medtech vet Patrick Kullmann as its new CEO.

Kullmann has previously served in leadership positions at Johnson & Johnson (NYSE:JNJ), Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT), as well as operating in leadership positions with a number of startups.

“We’re very pleased to have Patrick join the Physeon team at such an exciting time in its evolution. Patrick’s background, experience and accomplishments makes him a perfect leader for the organization,” Physeon parent company Novintum Medical Tech CEO Alan Wilson said in a prepared statement.

“I’m thrilled to join the Physeon team as it continues to move toward the anticipated US clinical trial with its disruptive Veinplicity device for venous access. I am confident that my background in leading highly successful teams will translate into establishing and executing a successful FDA trial strategy for future US approval,” Kullmann said in a press release.

Read more

 Raumedic CEO Bayer moves to N.C.

Raumedic said last week its prez and CEO Martin Bayer is moving his office to North America, looking to lead the company from its Mills River, N.C.-based site which is currently under construction.

Last month, Bayer was tapped as board chair for the company, which is looking to establish itself in the US market. In addition to Bayer’s promotion and move, the company said that COO Martin Schenkel was also tapped as board member for the company.

“I look forward to devoting myself to this task, and being on site will provide me with the best conditions,” Bayer said in a press release.

Read more

 TearLab CFO Brazell to resign, Marquez steps in as interim

TearLab Corp. (OTC:TEAR) said late last month that its chief financial officer Wes Brazell is resigning from the company, effective March 30.

The San Diego, Calif.-based company said that the board of directors has appointed finance senior director Michael Marquez as its interim CFO, also effective March 30.

Prior to his time with TearLab, Marquez held positions with Alcon Laboratories and Price Waterhouse Coopers, the company said.

Read more

  • Intuitive Surgical taps Bradshaw as first UK & Ireland GM
  • Milestone Scientific names Smith as sales & marketing EVP
  • CHF Solutions adds Powers as marketing VP
  • Precision Therapeutics appoints Hungerford as sales & marketing VP
  • Frequency Therapeutics taps LeBel as EVP

Filed Under: Business/Financial News Tagged With: Boston Scientific, CHF Solutions Inc., Endologix, endospan, Frequency Therapeutics, Intuitive Surgical, Invuity, Johnson and Johnson, Medtronic, milestonescientific, OmniGuide, Physeon, Precision Therapeutics Inc., Raumedic, Tearlab Corp.

In case you missed it

  • They said it at DeviceTalks Boston
  • Elucid raises $27M for heart disease diagnosis software
  • Summer health technology program brings diverse group of interns to Silicon Valley
  • BioSig expects to raise $3.5M from public offering
  • Haemonetics completes move to new Pennsylvania manufacturing facility
  • Vivera adds two industry veterans to its technology advisory board
  • Abbott Fund grants $750k to education, health equity program
  • Another Medtronic HVAD recall is serious
  • Endologix reports positive results from percutaneous bypass trial
  • NorthStar Medical names new president and chief operating officer
  • Vektor Medical names Rob Krummen as CEO
  • Baxter’s Volara lung therapy system recall is Class I
  • BD voluntarily recalls intraosseous products
  • Bioventus restructures $315M CartiHeal acquisition
  • Intrommune extends scope of Phase 1 trial for peanut-allergy-treating toothpaste
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
  • Hamilton Medical warns on some ventilators

RSS From Medical Design & Outsourcing

  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]
  • Clippard releases new series of isolation valves
    Clippard (Cincinnati) has Its Clippard NIV Series media isolation valve — a solenoid-operated device using a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves find everyday use in a wide variety of applications. Think uses that require precise, repeatable dispensing of media for analytical instrumentation. Clippard says media isolation… […]
  • Another Medtronic HVAD recall is serious
    A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this… […]
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
    SeaStar Medical recently won FDA breakthrough device designation for a new way to treat hyperinflammation with technology that could help fight chronic conditions from COVID-19 infections. The Denver-based medical developer is seeking a humanitarian device exemption for treating children with acute kidney injury (AKI) based on an FDA-funded study, SeaStar President and CEO Eric Schlorff… […]
  • How Avail Medsystems seeks to create a connected OR experience
    Much like a normal Starbucks-goer expects the coffee to taste a certain way at any location, Daniel Hawkins wants that type of experience in the operating room. Hawkins is the CEO of Avail Medsystems, a company developing telemedicine equipment that can connect surgeons, interventional specialists and medical device sales reps. Hawkins and the team at Avail… […]
  • How to leverage technology to drive diversity in clinical studies
    Convenience was the driver, and the traditional clinical trial model had to evolve when it came to a colorectal cancer screening study. The clinical study had 35,000 patients across the U.S. Chuanbo Xu, Freenome Cancer doesn’t discriminate. It’s the second-leading cause of death in the U.S. Early detection is key in treating — and even… […]
  • Medical device licensing pitfalls to avoid
    Prevent costly disputes caused by these common mistakes in patent license agreements. Marcelo Barros, Kathleen Daley, Brian Kacedon and Matthew Ritter, Finnegan Licensing and other technology transfer agreements can be critical for medical device companies that invest significantly into new technology R&D and seek and obtain intellectual property protection for those investments. But if these agreements… […]
  • Tolerance stack-up: Insight into the inner workings of high-density microelectronic medical devices
    Tolerance stack-up is a defining design concept to ensure new products are built efficiently and effectively.  Darren Gilmer, Intricon At a time when the future of micro-miniature medical devices seems unlimited, one fundamental reality remains firmly in place — the sizes and shapes of human anatomy. From blood vessels to ear canals, respiratory passages to… […]
  • Deburring and finishing for beautiful, functional medical devices
    The latest automated cutting tools help medical device manufacturers meet strict specs and high demand. Dave Sawicki, Xebec Increasing demand and advances in technology are driving growth in the medical device industry. Chronic diseases are more prevalent, and the aging population is larger, contributing to the demand for highly regulated Class III medical devices such… […]
  • FDA seeking innovations to move beyond heater-cooler device problems
    The FDA issued a notice today saying that it is working to evaluate new strategies to mitigate infections associated with heater-cooler devices. According to the notice, the administration is collaborating with professional societies, public health partners, heater-cooler manufacturers, and experts on the matter surrounding the heater-cooler devices used during medical and surgical procedures to warm… […]

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS